Skip to main content
SpringerLink
Log in

The decrease of serum luteinizing hormone level by a gonadotropin-releasing hormone antagonist following the mild IVF stimulation protocol for IVF and its clinical outcome

  • Assisted Reproduction
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose

While performing the mild ovarian stimulation protocol with a GnRH antagonist, the pregnancy rate was compared between the groups, which were divided by the degree that the luteinizing hormone (LH) level decreased.

Materials and methods

Patients aged 27 to 42years (36.1 ± 3.79) underwent 308 IVF cycles who opted for IVF via the mild ovarian stimulation protocol began clomiphene citrate on day 3 and recombinant FSH on day 5. A GnRH antagonist was administered when the dominant follicle reached 14mm. Serum LH was measured at the time of GnRH antagonist administration and at the time of hCG injection. The pregnancy rate and implantation rate were compared between 50 cycles in which the LH level dropped less than one-third and the control (LH level within 1/3).

Result(s)

The pregnancy rate for the group in which the LH level fell less than one third was 18%. Conversely, the pregnancy rate for the control group was 39%. The implantation rate was 18% for the less than one-third group and 26% for the control group. Both the pregnancy rate and the implantation rate for the group in which the LH level fell less than one-third were significantly lower than that of control (p < 0.02).

Conslusion(s)

When performing the mild ovarian stimulation protocol, serum LH should be followed. If the serum LH level is less than one-third at the time of hCG injection, both the pregnancy rate and implantation rate are significantly lower.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Branigan EF, Estes MA. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression. Fertil Steril 2000;73(3):587–90.

    Article  PubMed  CAS  Google Scholar 

  2. Weigert M, Krischker U, Pohl M, Poschalko G, Kindermann C, Feichtinger W. Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study. Fertil Steril 2002;78(1):34–9.

    Article  PubMed  Google Scholar 

  3. Williams SC, Gibbons WE, Muasher SJ, Oehninger S. Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist. Fertil Steril 2002;78(5):1068–72.

    Article  PubMed  Google Scholar 

  4. Craft I, Gorgy A, Hill J, Menon D, Podsiadly B. Will GnRH antagonists provide new hope for patients considered ‘difficult responders’ to GnRH agonist protocols? Hum Reprod 1999;14(12):2959–62.

    Article  PubMed  CAS  Google Scholar 

  5. Nikolettos N, Al-Hasani S, Felberbaum R, Demirel LC, Kupker W, Montzka P, et al. Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol 2001;97(2):202–7.

    Article  PubMed  CAS  Google Scholar 

  6. Tavaniotou A, Albano C, Smitz J, Devroey P. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist. Fertil Steril 2002;77(4):733–7.

    Article  PubMed  Google Scholar 

  7. Hwang JL, Huang LW, Hsieh BC, Tsai YL, Huang SC, Chen CY, et al. Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles. Hum Reprod 2003;18(1):45–9.

    Article  PubMed  CAS  Google Scholar 

  8. Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 1998;13(9):2411–4.

    Article  PubMed  CAS  Google Scholar 

  9. Diedrich K, Diedrich C, Santos E, Bauer O, Zoll C, al-Hasani S, et al. [Suppression of endogenous LH increase in ovarian stimulation with the GnRH antagonist Cetrorelix]. Geburtshilfe Frauenheilkd 1994;54(4):237–40.

    Article  PubMed  CAS  Google Scholar 

  10. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000;15(3):526–31.

    Article  PubMed  CAS  Google Scholar 

  11. Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 2003;88(1):166–73.

    Article  PubMed  CAS  Google Scholar 

  12. Gardner DK, Schoolcraft WB, Wagley L, Schlenker T, Stevens J, Hesla J. A prospective randomized trial of blastocyst culture and transfer in in-vitro fertilization. Hum Reprod 1998;13(12):3434–40.

    Article  PubMed  CAS  Google Scholar 

  13. Pelinck MJ, Vogel NE, Hoek A, Arts EG, Simons AH, Heineman MJ. Minimal stimulation IVF with late follicular phase administration of the GnRH antagonist cetrorelix and concomitant substitution with recombinant FSH: a pilot study. Hum Reprod 2005;20(3):642–8.

    Article  PubMed  CAS  Google Scholar 

  14. Weghofer A, Margreiter M, Bassim S, Sevelda U, Beilhack E, Feichtinger W. Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age. Fertil Steril 2004;81(4):1002–6.

    Article  PubMed  CAS  Google Scholar 

  15. Minaretzis D, Alper MM, Oskowitz SP, Lobel SM, Mortola JF, Pavlou SN. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells. Am J Obstet Gynecol 1995;172(5):1518–25.

    Article  PubMed  CAS  Google Scholar 

  16. Eldar-Geva T, Zylber-Haran E, Babayof R, Halevy-Shalem T, Ben-Chetrit A, Tsafrir A, et al. Similar outcome for cryopreserved embryo transfer following GnRH-antagonist/GnRH-agonist, GnRH-antagonist/HCG or long protocol ovarian stimulation. Reprod Biomed Online 2007;14(2):148–54.

    Article  PubMed  Google Scholar 

  17. Lee JR, Choi YS, Jee BC, Ku SY, Suh CS, Kim KC, et al. Cryopreserved blastocyst transfer: impact of gonadotropin-releasing hormone agonist versus antagonist in the previous oocyte retrieval cycles. Fertil Steril 2007;88(5):1344–9.

    Article  PubMed  CAS  Google Scholar 

  18. Tesarik J, Hazout A, Mendoza C. Luteinizing hormone affects uterine receptivity independently of ovarian function. Reprod Biomed Online 2003;7(1):59–64.

    Article  PubMed  CAS  Google Scholar 

  19. Licht P, von Wolff M, Berkholz A, Wildt L. Evidence for cycle-dependent expression of full-length human chorionic gonadotropin/luteinizing hormone receptor mRNA in human endometrium and decidua. Fertil Steril 2003;79(Suppl 1):718–23.

    Article  PubMed  Google Scholar 

  20. Ziecik AJ, Bodek G, Blitek A, Kaczmarek M, Waclawik A. Nongonadal LH receptors, their involvement in female reproductive function and a new applicable approach. Vet J 2005;169(1):75–84.

    Article  PubMed  CAS  Google Scholar 

  21. Kawate N, Tsuji M, Tamada H, Inaba T, Sawada T. Inhibition of luteinizing hormone receptor expression during the development of caprine corpora lutea by administration of gonadotropin-releasing hormone antagonist. Mol Reprod Dev 2002;63(4):444–50.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Denentoshi Ladies Clinic Reproductive Center, 2-3-10-5F Aoba-ku, Yokohama-shi, Kanagawa, 227-0062, Japan

    Atsushi Yanaihara, Takeshi Yorimitsu, Hiroshi Motoyama, Motohiro Ohara & Toshihiro Kawamura

  2. Department of Obstetrics and Gynecology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan

    Atsushi Yanaihara

Authors
  1. Atsushi Yanaihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Yorimitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroshi Motoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Motohiro Ohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toshihiro Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atsushi Yanaihara.

Additional information

Capsule If the serum LH level is less than one-third at the time of hCG injection, both the pregnancy rate and implantation rate are significantly lower following the Mild IVF stimulation protocol.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yanaihara, A., Yorimitsu, T., Motoyama, H. et al. The decrease of serum luteinizing hormone level by a gonadotropin-releasing hormone antagonist following the mild IVF stimulation protocol for IVF and its clinical outcome. J Assist Reprod Genet 25, 115–118 (2008). https://doi.org/10.1007/s10815-008-9205-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-008-9205-6

Keywords

Search

Navigation